Breaking Ground in Drug Discovery: Unravel Unveils rareSHIFT™ – A Revolutionary End-to-End Solution

BOSTON, Sept. 18, 2023 /PRNewswire/ — Unravel Biosciences, Inc., (“Unravel”), a pioneer in therapeutics powered by cutting-edge machine learning, is set to revolutionize the landscape of drug discovery with rareSHIFT™. This groundbreaking initiative promises to fast-track the development of patient-focused medicines at an unprecedented pace.

Neal I. Muni, M.D., MSPH, Chief Medical Officer at Unravel, commented, “Unravel has forged an ingenious drug discovery platform, the backbone of our innovative asset pipeline. In response to the urgent calls from patients, caregivers, and physicians to expedite treatments for complex, high-unmet-need conditions, we’re extending our mission. With rareSHIFT™, we’re opening up access to our capabilities for foundations and industry partners, heralding a paradigm shift in the identification of highly effective treatment options.”

rareSHIFT™ extends a warm invitation to partners, granting them access to Unravel’s comprehensive suite of world-class discovery and development tools, meticulously designed for a seamless journey to clinical fruition. The initiative encompasses patient RNAseq data generation through convenient home collection, facilitating patient population stratification. BioNAV™, a formidable AI network model with a deep grasp of over 40,000 compounds’ true potential, predicts therapeutic targets and drug candidates guided by patients’ RNA signatures.

SquishyWare™ steps in with on-demand CRISPR-engineered in vivo models for genetic disorders, facilitating swift screening with clinically-relevant metrics from day one. The integrated drug prototyping process leverages existing drugs to de-risk novel targets and repurposing prospects, unlocking the path to even more effective novel therapeutics.

Dr. Vinodh Narayanan, M.D., a pediatric neurologist at Arizona Pediatric Neurology and Neurogenetics Associates, emphasized, “Despite remarkable strides in gene-based therapies, the dire need for swift discoveries of small molecule treatments for genetic neurological disorders persists. We must drastically reduce the timeline from gene discovery to FDA approval for compounds.”

Kasey Edwards, CureAP4 Foundation Co-Founder and Community Coordinator, expressed, “Rare diseases cast a long shadow of uncertainty over the lives they touch. However, initiatives like rareSHIFT™ are beacons of hope, offering the potential for rapid discovery of effective treatments and brightening our path forward.”

About Unravel Biosciences

Unravel Biosciences stands as a trailblazer in the realm of rapid prototyping for therapeutics. The company’s prowess lies in its unique fusion of cutting-edge AI systems biology computation with lightning-fast in vivo screening and the rigorous clinical validation of newly unearthed targets, all achieved with unparalleled efficiency.

At the heart of Unravel’s innovation is its coveted BioNAV™ platform, a revolutionary amalgamation that seamlessly integrates target and drug discovery, preclinical screening, and the pinpoint stratification of patients. This dynamic synergy has led to the discovery of two remarkable gems in the therapeutic landscape: RVL002, an avant-garde small molecule targeting mitochondrial metabolism, wielding the potential to combat a spectrum of CNS and metabolic disorders, and RVL027, a groundbreaking molecule zeroing in on a novel mechanism for the treatment of dystonias.

Leave a Comment